MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease

New England Journal of Medicine

Volumn 379, Issue 23, 2018, Pages 2209-2219

  Juge, P A ^a,f,g   Lee, J S ^y   Ebstein, E ^a   Furukawa, H ^ad,ae   Dobrinskikh, E ^y   Gazal, S ^af,ah   Kannengiesser, C ^b,f   Ottaviani, S ^a   Oka, S ^ae   Tohma, S ^ae   Tsuchiya, N ^ad   Rojas Serrano, J ^ai   Gonzalez Perez M I ^ai   Mejia M ^ai   Buendia Roldan I ^ai   Falfan Valencia R ^aj   Ambrocio Ortiz, E ^aj   Manali, E ^ak   Papiris, S A ^ak   Karageorgas, T ^am   Boumpas, D ^am   Antoniou, K ^an,ao   Van Moorsel, C H M ^ap   Van Der Vis, J ^ap   De Man, Y A ^ap   Grutters, J C ^ap   Wang, Y ^aq   Borie, R ^c,f   Wemeau Stervinou, L ⁿ   Wallaert, B ⁿ   Flipo, R M ⁿ   Nunes, H ^o   Valeyre, D ^o   Saidenberg Kermanac'H, N ^p,q,r   Boissier, M C ^p,q,r   Marchand Adam, S ^s   Frazier, A ^h   Richette, P ^h,i   Allanore, Y ^j   Sibilia, J ^t   Dromer, C ^u   Richez, C ^i,v   Schaeverbeke, T ^i,v   Liote H ^k   Thabut, G ^d,f   Nathan, N ^l   Amselem, S ^l,m   Soubrier, M ^w   Cottin, V ^x   Clement A ^l   Deane, K ^y   Walts, A D ^y   Fingerlin, T ^aa   Fischer, A ^y   Ryu, J H ^ar   Matteson, E L ^ar   Niewold, T B ^as   Assayag, D ^at   Gross, A ^au   Wolters, P ^au   Schwarz, M I ^y   Holers, M ^y   Solomon, J J ^ab   Doyle, T ^ag   Rosas, I O ^ag   Blauwendraat, C ^ac,al   Nalls, M A ^ac,al   Debray, M P ^e   Boileau, C ^b   Crestani, B ^c,f   Schwartz, D A ^y,z   Dieude P ^a,f   more..

^a BICHAT HOSPITAL   (France)

^b Departments of Genetics   (France)

^c Departments of Pulmonology A   (France)

^d Departments of Pulmonology B   (France)

^e Departments of Radiology   (France)

^f Service de Pneumologie A Département hospitalo universitaire FIRE   (France)

^g Arthritis Recherche et Développement   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ CNRS   (France)

^j INSERM   (France)

^k HÔPITAL TENON   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m ARMAND TROUSSEAU HOSPITAL   (France)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o Departments of Pulmonology   (France)

^p Departments of Rheumatology   (France)

^q AVICENNE HOSPITAL   (France)

^r UNIVERSITÉ PARIS 13   (France)

^s UNIVERSITY HOSPITAL OF TOURS   (France)

^t UNIVERSITÉ DE STRASBOURG   (France)

^u Service de Pneumologie   (France)

^v Service de rhumatologie   (France)

^w UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^x UNIVERSITÉ LYON 1   (France)

^y Departments of Medicine   (United States)

^z UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^aa Departments of Biomedical Research   (United States)

^ab DEPARTMENT OF MEDICINE   (United States)

^ac NATIONAL INSTITUTE ON AGING   (United States)

^ad UNIVERSITY OF TSUKUBA   (Japan)

^ae SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^af HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ag BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ah BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^ai Interstitial Lung Disease and Rheumatology Unit   (Mexico)

^aj INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^ak 2nd Pulmonary Medicine Department   (Mexico)

^al Data Tecnica International LLC   (United States)

^am Rheumatology and Clinical Immunology Unit   (United States)

^an UNIVERSITY OF ATHENS   (Greece)

^ao UNIVERSITY OF CRETE   (Greece)

^ap ST ANTONIUS HOSPITAL   (Netherlands)

^aq MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^ar Mayo Clinic College of Medicine   (United States)

^as NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^at MCGILL UNIVERSITY   (Canada)

^au UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 5B;

ADULT; AGED; ARTICLE; CASE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUC5B GENE; PATIENT RISK; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY; CHEMISTRY; COMPLICATION; FIBROSING ALVEOLITIS; GENETIC PREDISPOSITION; GENETICS; LUNG; ODDS RATIO; PATHOLOGY;

AGED; ARTHRITIS, RHEUMATOID; FEMALE; GAIN OF FUNCTION MUTATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-5B; ODDS RATIO; PROMOTER REGIONS, GENETIC;

EID: 85058236740     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1801562     Document Type: Article

References (42)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
2. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183: 372-8.
3. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62: 1583-91.
4. Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010; 49: 1483-9.
5. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156: 528-35.
6. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 2017; 76: 1700-6.
7. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics - a large multicentre UK study. Rheumatology (Oxford) 2014; 53: 1676-82.
8. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 2014; 19: 493-500.
9. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136: 1397-405.
10. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322-8.
11. Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47: 588-96.
12. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J 2017; 50(2): pii:1602419.
13. Fautrel B, Cukierman G, Joubert JM, Laurendeau C, Gourmelen J, Fagnani F. Characteristics and management of rheumatoid arthritis in France: analysis of a representative French national claims database resulting in an estimated prevalence of 0.35. Joint Bone Spine 2016; 83: 461-2.
14. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996; 39: 1711-9.
15. Juge PA, Borie R, Kannengiesser C, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 2017; 49(5): pii:1602314.
16. Helling BA, Gerber AN, Kadiyala V, et al. Regulation of MUC5B expression in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2017; 57: 91-9.
17. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503-12.
18. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 2011; 364: 1576-7.
19. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45: 613-20.
20. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309-17.
21. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 2013; 8(8): e70621.
22. Horimasu Y, Ohshimo S, Bonella F, et al. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 439-44.
23. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68: 436-41.
24. Lee MG, Lee YH. A meta-analysis examining the association between the MUC5B rs35705950 T/G polymorphism and susceptibility to idiopathic pulmonary fibrosis. Inflamm Res 2015; 64: 463-70.
25. van der Vis JJ, Snetselaar R, Kazemier KM, ten Klooster L, Grutters JC, van Moorsel CH. Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. Respirology 2016; 21: 712-7.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
27. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
28. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidencebased guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
29. Fingerlin TE, Zhang W, Yang IV, et al. Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genet 2016; 17: 74.
30. Zhu QQ, Zhang XL, Zhang SM, et al. Association between the MUC5B promoter polymorphism rs35705950 and idiopathic pulmonary fibrosis: a meta-analysis and trial sequential analysis in Caucasian and Asian populations. Medicine (Baltimore) 2015; 94(43): e1901.
31. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506: 376-81.
32. Johnson C, Rosen P, Lloyd T, et al. Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respir Med 2017; 130: 52-4.
33. Assayag D, Lee JS, King TE Jr. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires) 2014; 74: 158-65.
34. Bernstein EJ, Barr RG, Austin JHM, et al. Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax 2016; 71: 1082-90.
35. Ley B, Newton CA, Arnould I, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med 2017; 5: 639-47.
36. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 2014; 270: 583-8.
37. Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013; 368: 2192-200.
38. Restrepo JF, del Rincón I, Battafarano DF, Haas RW, Doria M, Escalante A. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol 2015; 34: 1529-36.
39. Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int 2016; 36: 881-9.
40. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44: 291-6.
41. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.
42. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.